Lioresal Intrathecal (Baclofen)

Baclofen is a selective agonist of GABA_B receptors in the spinal cord. Activation of these metabotropic receptors inhibits calcium channels, reducing the release of excitatory neurotransmitters such as glutamate. This dampens spinal reflex activity, leading to decreased muscle tone and relief of spasticity.

The dosage of Lioresal Intrathecal is individualized and determined by the prescribing physician based on the patient’s severity of spasticity, prior response to oral baclofen, and tolerance. Dose titration is performed under specialist supervision to achieve optimal symptom control while minimizing adverse effects.

Safety data for intrathecal baclofen in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies. Breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Intrathecal delivery bypasses the blood‑brain barrier, allowing lower total doses and higher concentrations at the spinal cord compared with oral baclofen. This can result in greater spasticity control with fewer systemic side effects. However, it requires surgical implantation of a delivery pump and ongoing catheter maintenance, whereas oral therapy is non‑invasive.

Store the intrathecal solution at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct light, moisture and extreme temperature fluctuations. Do not freeze or shake the vial, and keep it out of reach of children.

Lioresal Intrathecal is administered via an implanted infusion pump that delivers the baclofen solution directly into the cerebrospinal fluid through a catheter placed in the intrathecal space. The pump is programmed by a qualified clinician to deliver a continuous or programmable dose according to the patient’s therapeutic needs.

The most serious risks include respiratory depression, severe hypotonia, seizures, and infection such as meningitis or catheter‑related sepsis. Abrupt discontinuation can cause rebound spasticity, which may be life‑threatening. Patients should be monitored closely, especially during dose changes or pump malfunction, and any signs of infection or neurological decline require immediate medical attention.

Lioresal Intrathecal is contraindicated in patients with known hypersensitivity to baclofen or any component of the formulation, active infection at the catheter insertion site, or uncontrolled severe cardiac or respiratory disease. It should also be avoided in individuals for whom surgical implantation of an intrathecal pump is not feasible or who cannot adhere to the required follow‑up and monitoring schedule.